Effects of novel androgen receptor signaling inhibitors on PSMA PET signal intensity in patients with castrate-resistant prostate cancer: a prospective exploratory serial imaging study.

"Declarations Ethics approval and consent to participateThe UCLA Internal Review Board (IRB) approved the study: IRB#19-002024. The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments. A written informed consent was obtained from all participants. Consent for publicationWritten informed consent was obtained from the patient for publication of this study and accompanying images. Competing interestsThe authors declare that they have no competing interests. Competing interests The authors declare that they have no competing interests."

"Funding AD reports consulting fees by Bristol-Myers Squibb, Astra-Zeneca, Radmetrix, Seattle Genetics, Janssen, PACT Pharma, Merck, Roche/Genentech, Exelixis and Dyania Health, research grants from Kite/Gilead and support to her institution by Astra-Zeneca, Genentech/Roche, Merck Sharp & Dohme, Jounce Therapeutics, Infinity Pharmaceuticals and Seattle Genetics/Astellas. MBR reports consulting fees by Progenics, Amgen, INmune Bio, Bayer, Astra-Zeneca, Myovant Speakers’ Bureau: Bayer, Janssen, and research funding from Novartis, Merck and Progenics. JCz is a founder of Sofie Bioscience, scientific founder of Trethera Corporation, is part of the medical advisory board of Amgen and Rayzie Bio, outside of the submitted work. JCa reports grants from support to his institution by Lantheus, Novartis, and POINT biopharma, consulting fees for lectures or advisory boards from Advanced Accelerator Applications, Amgen, Astellas, Bayer, Blue Earth Diagnostics Inc., Curium Pharma, DS Pharma, GE Healthcare, Isoray, IBA RadioPharma, Janssen Pharmaceuticals, Monrol, Lightpointmedical, Lantheus, Novartis, POINT biopharma, Progenics, Radiomedix, Sanofi, Telix Pharmaceuticals, outside of the submitted work."

"Conclusions: Our prospective trial involving 9 mCRPC patients initiating ARSi did not show significant modulation of PSMA expression measured on WB-PSMA PET at 1-week. This study was registered on clinicaltrials.gov (NCT04279561)."